|

Decitabine/cedazuridine Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Early-stage BAP1-associated Malignancies1
  • Subclinical Mesothelioma1
  • Early-stage Mesothelioma1
  • Malignant Mesothelioma (MM)1
  • BRCA1-Associated Protein-1 (BAP1) Mutations1

Bethesda, Maryland1 trial

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

National Institutes of Health Clinical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.